Health

Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer, Upcoming Webinar Hosted by Xtalks

Leave a comment


This webinar will address the importance of thorough target validation in the initial stages of pharmaceutical development, as incomplete preclinical validation can lead to efficacy and toxicity setbacks.


TORONTO (PRWEB)

Currently, chemotherapy is the primary mode of treatment for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of pancreatic cancer. However, selection of regimens is mainly based on patient performance and expected efficacy. The establishment of molecular predictors of chemotherapeutic efficacy is crucial to improve patient prognosis through personalized treatment based on molecular analysis.

The Pancreatic Cancer Team at the Cancer Research Center of Marseille has developed RNA-based signatures to predict the efficacy of all drugs used to treat PDAC. They utilized preclinical models such as PDAC primary cell cultures (PCC), patient-derived xenografts (PDX) and patient-derived organoids (PDO) to overcome limitations of individual models. By combining all three, they produced unbiased RNA-based signatures that are predictive of chemotherapeutic treatments in PDAC. This strategy has yielded improved predictive signatures validated in different patient cohorts, which have demonstrated significant associations with overall, disease-free and progression-free survival.

This webinar will address the importance of thorough target validation in the initial stages of pharmaceutical development, as incomplete preclinical validation can lead to efficacy and toxicity setbacks. The webinar will also highlight strategies for investigating target validation with a focus on PDAC 2D and 3D cell models, including the use of CRISPR target modulation and real-time proliferation. These innovative approaches hold great promise for advancing the field of drug discovery and personalized medicine in pancreatic cancer.

Join the featured speakers for an informative webinar on unlocking the synergy in preclinical models and the importance of target validation for the personalized treatment of pancreatic cancer.

Join Dr. Nelson Dusetti, Research Director at the Cancer Research Center of Marseille, INSERM U.1068; and Dr. Nicolas Ancellin, Senior Program Director/Site Director, Strategic Projects, Oncodesign Services, for the live webinar on Tuesday, May 16, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Leave a Reply